| Item Type | Name |
|
Concept
|
Renin-Angiotensin System
|
|
Concept
|
Renin
|
|
Academic Article
|
Role of vasopressin in essential hypertension: racial differences.
|
|
Academic Article
|
The renin-angiotensin system in diabetic nephropathy: the endothelial connection.
|
|
Academic Article
|
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
|
Academic Article
|
Clinical implications of blockade of the renin-angiotensin system in management of hypertension.
|
|
Academic Article
|
Protecting renal function in the hypertensive patient: clinical guidelines.
|
|
Academic Article
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
|
Academic Article
|
The cardiometabolic syndrome and calcium channel blocker combination drugs.
|
|
Academic Article
|
beta-blocker use and diabetes symptom score: results from the GEMINI study.
|
|
Academic Article
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
|
Academic Article
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
|
Academic Article
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
|
Academic Article
|
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
|
|
Academic Article
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
|
Academic Article
|
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
|
Academic Article
|
The kidney, hypertension, and remaining challenges.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors.
|
|
Academic Article
|
The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol.
|
|
Academic Article
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
|
Academic Article
|
Renal adaptation to the failing heart. Understanding the cascade of responses.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
|
|
Academic Article
|
Renal hemodynamic changes in heart failure.
|
|
Academic Article
|
ASH position paper: treatment of hypertension in patients with diabetes-an update.
|
|
Academic Article
|
Combination therapy in hypertension.
|
|
Academic Article
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
|
Academic Article
|
Pathogenesis and clinical physiology of hypertension.
|
|
Academic Article
|
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
|
|
Academic Article
|
A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique?
|
|
Academic Article
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
|
Academic Article
|
Renin-angiotensin blockade and kidney disease.
|
|
Academic Article
|
The future of blood pressure control in a population with a growing girth.
|
|
Academic Article
|
Is blockade of the renin-angiotensin system appropriate for all patients with diabetes?
|
|
Academic Article
|
Dual RAAS blockade is desirable in kidney disease: con.
|
|
Academic Article
|
Hypertensive nephropathy: prevention and treatment recommendations.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
The past, present and future of renin-angiotensin aldosterone system inhibition.
|
|
Academic Article
|
Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies.
|
|
Academic Article
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
|
Academic Article
|
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
New agents for hyperkalemia.
|
|
Academic Article
|
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
|
|
Academic Article
|
Advances in treatment of hyperkalemia in chronic kidney disease.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
|
|
Academic Article
|
Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
|
|
Academic Article
|
Renal Denervation: a Field in Flux.
|
|
Academic Article
|
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model.
|
|
Academic Article
|
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Hypertension.
|
|
Academic Article
|
Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia.
|
|
Academic Article
|
Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.
|
|
Academic Article
|
Slowing the Progression of Diabetic Kidney Disease.
|